Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Retained Earnings (2022 - 2025)

Historic Retained Earnings for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Q3 2025 value amounting to -$640.1 million.

  • Day One Biopharmaceuticals' Retained Earnings fell 3107.46% to -$640.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$640.1 million, marking a year-over-year decrease of 3107.46%. This contributed to the annual value of -$554.1 million for FY2024, which is 2082.41% down from last year.
  • As of Q3 2025, Day One Biopharmaceuticals' Retained Earnings stood at -$640.1 million, which was down 3107.46% from -$620.4 million recorded in Q2 2025.
  • In the past 5 years, Day One Biopharmaceuticals' Retained Earnings ranged from a high of -$155.2 million in Q1 2022 and a low of -$640.1 million during Q3 2025
  • In the last 4 years, Day One Biopharmaceuticals' Retained Earnings had a median value of -$458.6 million in 2023 and averaged -$421.2 million.
  • Per our database at Business Quant, Day One Biopharmaceuticals' Retained Earnings crashed by 10102.62% in 2023 and then plummeted by 1325.92% in 2025.
  • Over the past 4 years, Day One Biopharmaceuticals' Retained Earnings (Quarter) stood at -$269.7 million in 2022, then crashed by 70.06% to -$458.6 million in 2023, then decreased by 20.82% to -$554.1 million in 2024, then decreased by 15.53% to -$640.1 million in 2025.
  • Its last three reported values are -$640.1 million in Q3 2025, -$620.4 million for Q2 2025, and -$590.1 million during Q1 2025.